menu toggle

Podcast: Conversations around interchangeability and biosimilar entries in new therapeutic categories

By AmerisourceBergen

Launches in ophthalmology and the first interchangeable insulin biosimilar in the U.S.  bring new opportunities for this exciting product class. Listen in as our experts discuss these developments. 

You can also listen and subscribe wherever you get your podcasts, like Apple or Spotify.

Continue the conversation

Learn more about our solutions for this important product category.
Topics:
Biosimilars Affordability Market access Regulatory

Related Content

Manufacturers

Education: The centerpiece of biosimilar adoption

Inverted color AmerisourceBergen icon
AmerisourceBergen
February 2023
Biosimilars adoption

Manufacturers

Podcast: Milestones for biosimilars in 2022 and looking ahead to 2023

Inverted color AmerisourceBergen icon
AmerisourceBergen
July 2022
Biosimilars podcast

Manufacturers

Webinar: Bracing for the Impact of Biosimilars: Navigating Terrain in the U.S. Market Landscape

AB-TB-Sq-Block
FormularyDecisions
May 2024
Chemical chain